107 related articles for article (PubMed ID: 24417912)
1. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
2. Low non-relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle-Thérapie Cellulaire observational study.
Garderet L; Ouldjeriouat H; Bekadja MA; Daguenet E; Bigot N; Vincent L; Roos-Weil D; Vignon M; Ikhlef S; Abraham J; Escoffre-Barbe M; Lioure B; Nacer RA; Lafon I; Mariette C; Karlin L; Morel P; Gilis L; Le Ray E; Blouet A; Nguyen Quoc S; Boffa JJ; Ronco P; Lambert J; Cornillon J
Br J Haematol; 2024 Apr; 204(4):1450-1458. PubMed ID: 37953476
[TBL] [Abstract][Full Text] [Related]
3. Treatment Pattern and Outcome of Newly Diagnosed Multiple Myeloma Patients in a Resource-Limited Setting.
Cheong CS; Tengku K Aziz TAH; Anuar NA; Bee PC; Chin EFM; Khairullah S; Liong CC; Zamri Y; Gan GG
Asian Pac J Cancer Prev; 2024 Feb; 25(2):595-601. PubMed ID: 38415546
[TBL] [Abstract][Full Text] [Related]
4. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323
[TBL] [Abstract][Full Text] [Related]
5. Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response.
Lehners N; Becker N; Benner A; Pritsch M; Löpprich M; Mai EK; Hillengass J; Goldschmidt H; Raab MS
Cancer Med; 2018 Feb; 7(2):307-316. PubMed ID: 29282899
[TBL] [Abstract][Full Text] [Related]
6. High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Pineda-Roman M; Barlogie B; Anaissie E; Zangari M; Bolejack V; van Rhee F; Tricot G; Crowley J
Cancer; 2008 Apr; 112(8):1754-64. PubMed ID: 18300230
[TBL] [Abstract][Full Text] [Related]
7. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma.
Gul Z; Bashir Q; Cremer M; Yusuf SW; Gunaydin H; Arora S; Slone S; Nieto Y; Sherwani N; Parmar S; Shah N; Dinh YT; Hosing CM; Popat UR; Kebriaei P; Shpall EJ; Giralt SA; Champlin RE; Qazilbash MH
Leuk Lymphoma; 2015 Feb; 56(2):533-5. PubMed ID: 24882259
[No Abstract] [Full Text] [Related]
8. Immunomodulatory drugs improve the immune environment for dendritic cell-based immunotherapy in multiple myeloma patients after autologous stem cell transplantation.
De Keersmaecker B; Fostier K; Corthals J; Wilgenhof S; Heirman C; Aerts JL; Thielemans K; Schots R
Cancer Immunol Immunother; 2014 Oct; 63(10):1023-36. PubMed ID: 24947180
[TBL] [Abstract][Full Text] [Related]
9. Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients.
Abdrabou AK; Al Sharif F; El Fakih R; Zahrani HA; Al Yamany R; Saleh M; Alhayli S; Al Somali Z; Alotaibi A; AlShaibani A; Deeba F; Asif M; Ahmed SAOA; Al Fraih F; Shaheen M; Alahmari A; Rasheed W; Chaudhri NA; Al Mohareb F; Aljurf M; Hanbali A
Ann Saudi Med; 2024; 44(2):93-103. PubMed ID: 38615184
[TBL] [Abstract][Full Text] [Related]
10. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.
Beksac M; Eikema DJ; Koster L; Hulin C; Poiré X; Hamladji RM; Gromek T; Bazarbachi A; Ozkurt ZN; Pabst T; Ben Othman T; Finke J; Pirogova O; Wu D; Hayat A; Hilgendorf I; Tholouli E; de Wreede LC; Schönland S; Garderet L; Drozd-Sokolowska J; Raj K; Hayden PJ; Yakoub-Agha I; McLornan DP
Bone Marrow Transplant; 2024 Apr; 59(4):526-533. PubMed ID: 38297040
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma.
Lee SR; Kim SJ; Park Y; Sung HJ; Choi CW; Kim BS
Korean J Hematol; 2010 Sep; 45(3):183-7. PubMed ID: 21120207
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR.
Weisel K; Mateos MV; Gay F; Delforge M; Cook G; Szabo Z; Desgraz R; DeCosta L; Moreau P
Leukemia; 2021 Jun; 35(6):1732-1744. PubMed ID: 33067574
[TBL] [Abstract][Full Text] [Related]
13. High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Samur MK; Roncador M; Aktas Samur A; Fulciniti M; Bazarbachi AH; Szalat R; Shammas MA; Sperling AS; Richardson PG; Magrangeas F; Minvielle S; Perrot A; Corre J; Moreau P; Thakurta A; Parmigiani G; Anderson KC; Avet-Loiseau H; Munshi NC
Blood; 2023 Apr; 141(14):1724-1736. PubMed ID: 36603186
[TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation.
Pasvolsky O; Wang Z; Milton DR; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Tang G; Kebriaei P; Aljawai Y; Khan HN; Lee HC; Ye C; Patel KK; Thomas SK; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Blood Cancer J; 2024 May; 14(1):82. PubMed ID: 38760362
[TBL] [Abstract][Full Text] [Related]
15. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
Pasvolsky O; Pasyar S; Bassett RL; Khan HN; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
Cancer; 2024 May; 130(9):1663-1672. PubMed ID: 38127583
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of repeat myeloablative chemotherapy with autologous stem-cell support in multiple myeloma.
Menzel H; Hinmüller K; Kolb HJ; Schuster T; Hoellein A; Peschel C; Dechow T; Keller U
Ther Adv Hematol; 2012 Apr; 3(2):81-8. PubMed ID: 23556114
[TBL] [Abstract][Full Text] [Related]
17. Early M-protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high-risk cytogenetic multiple myeloma.
Zhu H; Liu J; Gu J; Chen M; Kuang L; Huang B; Zou W; Li J
Br J Haematol; 2024 Mar; 204(3):976-987. PubMed ID: 38246862
[TBL] [Abstract][Full Text] [Related]
18. A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation.
Scordo M; Shah GL; Adintori PA; Knezevic A; Devlin SM; Buchan ML; Preston EV; Lin AP; Rodriguez NT; Carino CA; Nguyen LK; Sitner NC; Barasch A; Klang MG; Maloy MA; Mastrogiacomo B; Carlow DC; Schofield RC; Slingerland AE; Slingerland JB; Stein-Thoeringer CK; Lahoud OB; Landau HJ; Chung DJ; van den Brink MRM; Peled JU; Giralt SA
Cancer; 2022 Nov; 128(21):3850-3859. PubMed ID: 36041227
[TBL] [Abstract][Full Text] [Related]
19. The Arkansas approach to therapy of patients with multiple myeloma.
Barlogie B; Anaissie E; van Rhee F; Pineda-Roman M; Zangari M; Shaughnessy J; Epstein J; Crowley J
Best Pract Res Clin Haematol; 2007 Dec; 20(4):761-81. PubMed ID: 18070718
[TBL] [Abstract][Full Text] [Related]
20. Genomic Classification and Individualized Prognosis in Multiple Myeloma.
Maura F; Rajanna AR; Ziccheddu B; Poos AM; Derkach A; Maclachlan K; Durante M; Diamond B; Papadimitriou M; Davies F; Boyle EM; Walker B; Hultcrantz M; Silva A; Hampton O; Teer JK; Siegel EM; Bolli N; Jackson GH; Kaiser M; Pawlyn C; Cook G; Kazandjian D; Stein C; Chesi M; Bergsagel L; Mai EK; Goldschmidt H; Weisel KC; Fenk R; Raab MS; Van Rhee F; Usmani S; Shain KH; Weinhold N; Morgan G; Landgren O
J Clin Oncol; 2024 Apr; 42(11):1229-1240. PubMed ID: 38194610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
